Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy

Abstract Background and aim The objective of this retrospective, observational, noninterventional cohort study was to investigate prognostic factors of overall survival (OS) in patients with advanced non‐small cell lung cancer (aNSCLC) and to develop a novel prognostic model. Methods A total of 4049...

Full description

Bibliographic Details
Main Authors: Cristina Julian, Robson J. M. Machado, Sandhya Girish, Pascal Chanu, Dominik Heinzmann, Chris Harbron, Anda Gershon, Shannon M. Pfeiffer, Wei Zou, Valerie Quarmby, Qing Zhang, Yachi Chen
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Cancer Reports
Subjects:
advanced NSCLC
immune checkpoint inhibitors
prognostic model
real‐world data
Online Access:https://doi.org/10.1002/cnr2.1578

Internet

https://doi.org/10.1002/cnr2.1578

Similar Items